NORCROSS, Ga., Jan. 31, 2013 /PRNewswire/ -- RayBiotech, Inc. announced today that it has executed a master services agreement with Banner Sun Health Research Institute (BSHRI) of Sun City, Arizona. Under the terms of the agreement, RayBiotech will provide priority services for the biochemical analysis of disease markers in biological samples. A particular focus of the pact will be on the characterization of key biomarkers for the study of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Financial terms were not disclosed.
RayBiotech's President, Chief Operating Officer and Co-Founder, Rani Huang stated, "We are excited about providing biomarker analysis services to BSHRI researchers. Banner Sun Health Research Institute is a unique world-class research organization that has outstanding tissue depository program, clinical center that conducts a large number of clinical trials, and research scientists who are dedicated to translational research in neurodegenerative and cardiovascular disorders. We believe that the collaboration will yield promising new opportunities facilitating early diagnosis of these devastating diseases."
BSHRI research scientists are involved in biomarker discovery research in both Alzheimer's and Parkinson's diseases. Senior Scientist Dr. LihFen Lue said, "As we continue to strive towards a better understanding of the molecular mechanisms at early stage of these neurodegenerative diseases, we also recognize the importance of identifying proteins present in the biofluid that could be used as potential disease biomarkers. Fortunately, we have more cutting-edge tools these days to do this crucial research. Raybiotech Quantibody® array is one of these very useful tools."
RayBiotech provides a valuable biochemical platform to assess both the identity and quantity of these markers in a comprehensive high-throughput for
|SOURCE RayBiotech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved